Aileron Therapeutics, Inc. (ALRN)
- Previous Close
3.2900 - Open
3.2200 - Bid --
- Ask --
- Day's Range
3.1650 - 3.2700 - 52 Week Range
1.0100 - 7.4200 - Volume
11,312 - Avg. Volume
93,449 - Market Cap (intraday)
69.95M - Beta (5Y Monthly) 2.10
- PE Ratio (TTM)
-- - EPS (TTM)
-3.2300 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
www.aileronrx.comRecent News: ALRN
Performance Overview: ALRN
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALRN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALRN
Valuation Measures
Market Cap
69.95M
Enterprise Value
52.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.94%
Return on Equity (ttm)
-34.21%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.07M
Diluted EPS (ttm)
-3.2300
Balance Sheet and Cash Flow
Total Cash (mrq)
12.04M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.21M